Hims Hers Health

Yahoo Finance • 4 days ago

A Look At Hims & Hers (HIMS) Valuation After GLP 1 Crackdown And Wegovy Pivot

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. The regulatory halt of Hims & Hers Health (HIMS) compounded weight... Full story

Yahoo Finance • 4 days ago

Hims And Hers Confronts Amazon Threat While Advancing AI Weight Loss Plan

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Amazon Pharmacy has entered the weight loss medication market with Eli Lilly’s new GLP-1 drug, o... Full story

Yahoo Finance • 7 days ago

Novo Nordisk Obesity And Diabetes Moves Tested Against Weak Share Performance

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Novo Nordisk has introduced a higher dose 7.2 mg version of Wegovy... Full story

Yahoo Finance • 7 days ago

Hims & Hers price target slashed amid GLP-1 transition

Hims & Hers price target slashed amid GLP-1 transition Proactive uses images sourced from Shutterstock Bank of America lowered its 2026 price target for Hims & Hers (NYSE:HIMS) to $21 from $23, citing peer multiple compression and near-t... Full story

Yahoo Finance • 7 days ago

HIMS Investors Have Opportunity to Join Hims & Hers Health, Inc. Fraud Investigation with the Schall Law Firm

LOS ANGELES, April 08, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Hims & Hers Health, Inc. (“Hims & Hers” or “the Compa... Full story

Yahoo Finance • 7 days ago

New Derivative Income ETFs Aren’t Worth the Risks

There are now a host of funds that use options to generate income from an individual stock. Here’s how they work—and why individual investors would be wise to steer clear. Continue Reading... Full story

Yahoo Finance • 8 days ago

The $190 Billion ‘Diabesity’ Market Is Set to Explode. Lilly and Novo Face These Stock Catalysts.

The recent fixation on weight-loss drugs, a catchall term referring to GLP-1 medications like Wegovy and Zepbound, has brought Eli Lilly and Novo Nordisk squarely into the limelight. The combined market for both indications—chronic weight... Full story

Yahoo Finance • 8 days ago

Hims & Hers Health (HIMS) Is Up 8.3% After Expanding Novo Nordisk GLP-1 Partnership And Launching New Weight-Loss Membership - Has The Bull Case Changed?

In late March 2026, Hims & Hers Health, Inc. announced a renewed collaboration with Novo Nordisk to offer a broad range of FDA-approved GLP-1 medications, including Wegovy injections and the only FDA-approved Wegovy weight loss pill, along... Full story

Yahoo Finance • 8 days ago

Hims & Hers (HIMS) Taps Into $200-Billion Weight Loss Market, Soars 6%

Hims & Hers Health Inc. (NYSE:HIMS) is one of the 10 Stocks With Unexpected Gains. Hims & Hers bounced back by 6.22 percent on Monday to close at $20.33 apiece, as investors positioned their second-quarter portfolios backed by optimism ov... Full story

Yahoo Finance • 14 days ago

Novo Partnership Fuels Long-Term Optimism for Hims & Hers Health, Inc. (HIMS)

Hims & Hers Health, Inc. (NYSE:HIMS) is among the 7 Best Stocks to Buy for Short Term. On March 27, Canaccord Genuity reiterated a Buy rating on Hims & Hers Health, Inc. (NYSE:HIMS) with a price target of $30. This reaffirmation comes afte... Full story

Yahoo Finance • 15 days ago

Hims GLP 1 Deal With Novo Nordisk Reshapes Growth And Valuation Story

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Hims & Hers Health (NYSE:HIMS) is expanding access to FDA-approved GLP-1 medications through a new collaboration with Novo Nordisk... Full story

Yahoo Finance • 15 days ago

Novo Nordisk launches first and only multi-month subscription program for FDA-approved Wegovy®, offering savings of up to $1,200/year

New subscription-based option helps eligible self-pay patients start and stay on Wegovy® with predictable pricing Available March 31, 2026, through Ro, WeightWatchers, LifeMD, with Hims & Hers, Sesame, and other telehealth providers coming... Full story

Yahoo Finance • 20 days ago

Sector Update: Health Care Stocks Advance Thursday Afternoon

Health care stocks rose Thursday afternoon, with the NYSE Health Care Index increasing 0.1% and the PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium... Full story

Yahoo Finance • 20 days ago

Novo Nordisk’s FDA-Approved GLP-1s Now Available With Hims & Hers

Starting today, eligible customers can access a broad assortment of treatment options, including the only FDA-approved GLP-1 weight loss pill. Starting today, eligible customers can access a broad assortment of treatment options, includin... Full story

Yahoo Finance • 22 days ago

Hims & Hers Health (HIMS) Valuation After Novo Nordisk Weight Loss Deal And Product Exit

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Executive moves and renewed weight loss partnership put Hims & Hers Health (HIMS) in focus Hims & Hers Health (HIMS)... Full story

Yahoo Finance • 23 days ago

2 Healthcare Stocks to Target This Week and 1 That Underwhelm

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Players catalyzing medical advancements have benefited from elevated demand, and their momentum is only rising as the... Full story

Yahoo Finance • 25 days ago

This Hims & Hers Move Could Destroy Competitors

Key Points The recent deal between Novo Nordisk and Hims & Hers is already resulting in new product announcements for Hims & Hers. The fastest GLP-1 launch in history could be boosted by a wider distribution funnel. This could bring gro... Full story

Yahoo Finance • 25 days ago

Does Hims & Hers (HIMS) Novo Nordisk Deal Quietly Redraw Its Risk Reward Profile?

Earlier in March 2026, Novo Nordisk agreed to resume selling its weight-loss drugs through the Hims & Hers Health platform, ending a public legal conflict over copycat medications and restoring a commercial relationship in one of healthcar... Full story

Yahoo Finance • 25 days ago

Why The Hims & Hers Health (HIMS) Story Is Resetting After Novo Deal And New Guidance

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. The modeled fair value for Hims & Hers Health has been revised from about US$44.36 to around US$23.69, a reset of roughly 4... Full story

Yahoo Finance • 26 days ago

Down Near Its 5-Year Low, Is Novo Nordisk Stock Too Cheap to Pass Up?

Key Points Novo Nordisk unveiled a troubling guidance for 2026, which tanked the stock. It recently reached a deal with telehealth company Hims & Hers Health to sell its GLP-1 products. The stock is trading at just 10 times its earnings.1... Full story